|
1 Company |
|
2 Products |
|
2 Products |
|
0 Mechanisms of Action |
|
0 Trials |
|
11 News |
|
- | timolol maleate ophthalmic solution / Generic mfg.
Trial completion date, Trial primary completion date: Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol (clinicaltrials.gov) - Apr 25, 2018
P1, N=10, Recruiting, Sponsor: Wills Eye
Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019
- | timolol maleate ophthalmic solution / Generic mfg.
Trial primary completion date: Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol (clinicaltrials.gov) - May 15, 2017
P1, N=10, Recruiting, Sponsor: Wills Eye
Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019 Trial primary completion date: Dec 2016 --> Dec 2017
- everolimus / Generic mfg.
Enrollment change, Trial withdrawal: Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) (clinicaltrials.gov) - May 5, 2016
P2, N=0, Withdrawn, Sponsor: Baylor College of Medicine
Trial primary completion date: Dec 2016 --> Dec 2017 N=25 --> 0 | Recruiting --> Withdrawn
- timolol maleate ophthalmic solution / Generic mfg.
Trial primary completion date: Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol (clinicaltrials.gov) - Dec 21, 2015
P1, N=10, Recruiting, Sponsor: Wills Eye
N=25 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Jul 2015 --> Dec 2016
- timolol maleate ophthalmic solution / Generic mfg.
Trial primary completion date: Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol (clinicaltrials.gov) - Dec 25, 2014
P1, N=10, Recruiting, Sponsor: Wills Eye
Trial primary completion date: Jul 2015 --> Dec 2016 Trial primary completion date: Jul 2014 --> Jul 2015
- | everolimus / Generic mfg.
Trial initiation date: Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) (clinicaltrials.gov) - Apr 22, 2014
P2, N=25, Recruiting, Sponsor: Baylor College of Medicine
Trial primary completion date: Jul 2014 --> Jul 2015 Initiation date: Dec 2013 --> Apr 2014
- | everolimus / Generic mfg.
Enrollment open: Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) (clinicaltrials.gov) - Apr 22, 2014
P2, N=25, Recruiting, Sponsor: Baylor College of Medicine
Initiation date: Dec 2013 --> Apr 2014 Not yet recruiting --> Recruiting
- New P2 trial: Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome (clinicaltrials.gov) - Mar 4, 2014
P2, N=23, Completed, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
- | everolimus / Generic mfg.
New P2 trial: Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) (clinicaltrials.gov) - Nov 26, 2013
P2, N=25, Recruiting, Sponsor: Baylor College of Medicine
- timolol maleate ophthalmic solution / Generic mfg.
Enrollment open: Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol (clinicaltrials.gov) - Dec 12, 2012
P1, N=10, Recruiting, Sponsor: Wills Eye
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- timolol maleate ophthalmic solution / Generic mfg.
New P1 trial: Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol (clinicaltrials.gov) - Feb 13, 2012
P1, N=10, Recruiting, Sponsor: Wills Eye